How Healthcare Advertising Turned Medicine Into a Marketing Budget
Let’s play a game. I’ll describe a scene, and you tell me if it’s a pharmaceutical commercial or an actual medical consultation. A photogenic couple runs through a field of lavender in slow motion. A golden retriever bounds alongside them. A soothing voiceover promises freedom, joy, and “talk to your doctor about whether this is right for you,” followed by ninety seconds of side effects that include, and I am not making this up, death. Then they go paddleboarding.
If you guessed “pharmaceutical commercial,” congratulations, you have functioning eyes and ears and have owned a television since 1997. If you guessed “medical consultation,” I need you to sit down, because I have some upsetting news about how the sausage actually gets made. The United States and New Zealand are the only two countries on Earth that allow direct-to-consumer (DTC) advertising of prescription drugs. Every other developed nation looked at this idea and said, politely but firmly, absolutely not. And yet here we are, a nation drowning in ads for drugs whose names sound like sequels to a dystopian trilogy, wondering out loud why healthcare costs so much. It’s not a mystery. It’s a marketing budget with a stethoscope taped to it.
The Math Nobody Wants You to Do
Let’s talk numbers, because numbers are the one thing that shuts up an argument faster than a toddler with a popsicle. In 1997, the FDA relaxed its rules on broadcast drug advertising, effectively opening the floodgates. Before that, DTC ad spending was $791 million a year. By 2016, it had ballooned to $9.6 billion, a roughly 460% increase, while total medical marketing spending climbed from $17.7 billion to $29.9 billion over the same period. By 2025, total direct-to-consumer healthcare advertising — drugs and hospitals combined — had climbed to an estimated $25 billion, up from $10 billion in 2016. Here’s the part where I remind you that pharmaceutical companies are not a charity. They are not spending $9.6 billion a year because they love you and want you to be informed. They are spending it because it works, spectacularly. One widely cited estimate found that every $1 spent on DTC pharmaceutical advertising generates roughly $4.20 in additional sales. That is an extraordinary return on investment for anything, let alone something ostensibly regulated as “medicine.” Your local casino would kill for those odds.
And who do you think is paying for that return on investment?
It isn’t coming out of shareholder yachts. It’s baked into the price of the pill, which is baked into your premium, which is baked into your deductible, which is why you’re currently having a staring contest with a $340 co-pay for a medication that costs $9 to manufacture.
“Ask Your Doctor” Is Doing a Lot of Heavy Lifting
The tagline “ask your doctor if this is right for you” sounds like responsible messaging. It is actually a beautifully engineered pressure campaign, and I say that as someone who has been on the receiving end of it in an exam room approximately four thousand times. Research on DTC advertising consistently shows the same pattern: patients see the ad, patients request the drug, and physicians write the prescription — a lot more often than you’d think a rigorous, evidence-based medical system would allow. In one landmark study comparing Sacramento (heavy DTC exposure) to Vancouver (essentially none), patients exposed to more advertising requested branded drugs at more than twice the rate, and physicians granted 72–78% of those requests regardless of the city. Patients who specifically requested an advertised drug were nearly 17 times more likely to walk out with a new prescription than patients who didn’t ask. Physicians themselves judged half of those requested prescriptions to be only “possible” or “unlikely” appropriate choices for a typical patient with that condition, compared to just 12% of unrequested prescriptions.
Let that sink in. Half. A coin flip on clinical appropriateness, driven by a commercial that aired during a rerun of a home renovation show. A broader systematic review of DTC advertising and prescription requests found the same thing across multiple studies: DTCA increases prescription requests, increases the likelihood of prescription, and increases both appropriate and inappropriate prescribing simultaneously. One survey found DTCA-driven inquiries account for roughly 4.5–5.2% of all outpatient visits, and those inquiries result in a prescription for the advertised drug 39–77% of the time. I want to be fair here, because sarcasm without substance is just yelling. There is a real, defensible argument that advertising raises awareness of undertreated conditions like depression, and one study found DTC-prompted requests increased appropriate antidepressant prescribing in patients who genuinely had major depression. Good. Genuinely good. But that same study found the opposite effect in patients with adjustment disorder, a much milder condition, where DTC-style requests drove prescribing up from 10% to 55%. So the same mechanism that occasionally catches a real problem is also, most of the time, manufacturing demand for problems that didn’t need a pill. That’s not a healthcare system responding to need. That’s a slot machine that occasionally pays out.
It’s Not Just Pills. Hospitals Do This Too.
If you thought this was purely a Big Pharma problem, I regret to inform you that your local hospital system has also discovered the magic of a well-placed billboard. American hospitals spend somewhere between $1.4 and $3.4 billion a year advertising themselves directly to consumers, and that spending has grown over 250% since the late 1990s. A rigorous new NBER working paper using Traditional Medicare claims data found that hospital advertising causally increases both patient volume and Medicare spending on inpatient care, and that for-profit hospitals specifically extract higher outpatient revenue from every advertising dollar. A separate study from the University of Pennsylvania’s Leonard Davis Institute quantified this with almost comedic precision: a 10% increase in a regional market’s hospital advertising (about 150 additional ad impressions) causes nine additional hospital admissions per 100,000 Medicare beneficiaries, driving an estimated $3.3 million in additional Medicare spending per year, per average market. Emergency department admissions were especially sensitive to advertising exposure, which should concern anyone who thought “should I go to the ER” was a medical decision rather than a marketing outcome.
And here’s my favorite detail, tucked into a cross-sectional study of over 4,500 hospitals: advertising spending had no meaningful association with objective, publicly reported measures of hospital quality. None. What it was strongly associated with was the hospital’s net income and financial assets. Translation: the hospitals doing the most billboard-and-jingle marketing aren’t necessarily the best hospitals. They’re the hospitals with the biggest marketing line item, because they had money left over after, presumably, everything else. A separate line of research even found that hospitals actually advertise more aggressively in markets that already have higher end-of-life healthcare spending, a proxy for wasteful, low-value care — a one standard deviation increase in that spending correlated with a 48% jump in total hospital advertising. So it’s not just that advertising drives excess utilization. Excess utilization and advertising appear to travel together, feeding off each other, like a raccoon and a dumpster.
“But Advertising Informs Patients!”
I know. I can already hear the rebuttal forming, possibly from an industry-funded fellow who will remind me that DTC advertising raises disease awareness, encourages people to seek care for undertreated conditions, and generates useful doctor-patient conversations. Some of that is even true. A Stanford analysis of the Medicare Part D rollout found that increased advertising exposure led to real increases in treatment initiation and improved medication adherence, with positive spillover effects on non-advertised generic drugs. Fine. Advertising is not purely evil. It is, however, overwhelmingly aimed at the wrong targets. An analysis of the most heavily advertised television drugs found that fewer than one-third were rated as having high therapeutic value, and roughly $15.9 billion of the $22.3 billion spent on TV drug ads went toward products offering only low or modest added clinical benefit over what already existed. A GAO analysis found that drugs with DTC advertising accounted for $324 billion of the $560 billion in total Medicare Part B and D drug spending from 2016–2018, with two-thirds of all DTC ad spending concentrated on just 39 brand-name drugs. So the honest version of “advertising informs patients” is: advertising overwhelmingly informs patients about the newest, most expensive, least differentiated brand-name option available, while your pharmacist’s generic alternative sitting quietly on the shelf gets zero airtime, because nobody’s marketing budget depends on you asking for the $4 version.
Who Actually Pays For the Puppy Commercial
This is the part where I stop being amusing and start being annoyed, because someone has to pay for that lavender field and that golden retriever, and it is not the pharmaceutical company’s marketing department eating the cost out of goodwill. The Congressional Budget Office estimates that a 10% increase in DTC advertising is associated with a 1–2.3% increase in overall drug spending. Other research found that a 10% increase in DTC ad exposure produces a 5.4% increase in the advertised product’s revenue and that broadcast advertising specifically accounts for about 19% of the overall growth in national drug expenditures over the study period, two-thirds of which came from higher demand and one-third from higher prices. Advertising budgets, in other words, are not a cost pharmaceutical companies quietly absorb. They are a cost that gets folded directly into what you and your insurance company pay at the counter, which is a nice way of saying the $340 co-pay I mentioned earlier is partially subsidizing a jingle. And because health economics loves a good twist ending: taxing or restricting pharmaceutical advertising could increase federal tax revenue by an estimated $1.5 to $1.7 billion annually from just the ten largest pharmaceutical companies, because ad spending is currently a fully deductible business expense. So not only are we paying for the ads through higher drug prices, we’re subsidizing the tax break on them too. It’s a marketing budget wearing a healthcare costume, and we keep RSVPing to the party.
The Bottom Line
Advertising in healthcare isn’t inherently satanic. It has, in narrow and specific circumstances, helped undertreated patients find real treatment for real conditions. But the overwhelming weight of the evidence says the system we’ve actually built does something much simpler and much less noble: it manufactures demand for the most expensive, least clinically differentiated products, funnels that demand through exam rooms and emergency departments, and hands the bill to patients, insurers, and taxpayers, all while producing no measurable improvement in the quality of care delivered. The commercial doesn’t care whether the drug is right for you. The commercial cares whether you’ll ask, because the moment you ask, the odds shift dramatically in the manufacturer’s favor. Every study on this topic points the same direction: more ads, more requests, more prescriptions, more spending, and no reliable bump in health outcomes to show for it.So the next time a golden retriever runs through a lavender field while a voiceover mentions “risk of death” in the same soothing tone used to describe a spa day, maybe don’t ask your doctor if it’s right for you. Ask why the ad exists in the first place. I promise you, the answer isn’t your wellbeing. It’s the quarterly earnings call.
“This blog is for general educational and informational purposes only and is not intended to provide medical advice, diagnosis, or treatment for any individual child, patient, or situation. Reading this site, commenting, or contacting the author does not create a doctor–patient relationship. The content may not reflect the most current pediatric or general medical standards and should not be used to make or delay medical decisions about your child’s health. Always consult your own licensed pediatrician or qualified healthcare provider for questions about your child’s health, and call 911 or your local emergency number in a medical emergency. The views expressed are solely those of the author and do not represent the opinions or policies of any employer, hospital, practice, institution, or professional organization. The author and site are not responsible for any actions taken based on the information provided on this blog.”
Source List
University of Pennsylvania Leonard Davis Institute of Health Economics. Hospital ads raised ER visits and Medicare spending, innovative LDI study says. Published 2026. https://ldi.upenn.edu/our-work/research-updates/hospital-ads-raised-er-visits-and-medicare-spending-innovative-ldi-study-says/
Franquiz MJ, McGuire AL. Direct-to-consumer drug advertisement and prescribing practices: evidence review and practical guidance for clinicians. J Gen Intern Med. 2020;36(5):1390-1394
Direct-to-consumer (DTC) pharmaceutical marketing: impacts and policy implications. SPNHA Review. Grand Valley State University. https://scholarworks.gvsu.edu/cgi/viewcontent.cgi?article=1013&context=spnhareview
Mintzes B, Barer ML, Kravitz RL, et al. How does direct-to-consumer advertising (DTCA) affect prescribing? A survey in primary care environments with and without legal DTCA. CMAJ. 2003;169(5):405-412.
Kravitz RL, Epstein RM, Feldman MD, et al. Influence of patients’ requests for direct-to-consumer advertised antidepressants: a randomized controlled trial. JAMA. 2005;293(16):1995-2002
Alpert AE, Gupta A, Richards MR, Schutz SD, Whaley CM. Does advertising expand the market for hospital services? Evidence from Medicare. NBER Working Paper 34657. National Bureau of Economic Research; 2026. https://www.nber.org/system/files/working_papers/w34657/w34657.pdf
Ndumele CD, Cohen MS, Solberg M, Lollo A, Wallace J. Characterization of US hospital advertising and association with hospital performance, 2008-2016. JAMA Netw Open. 2021;4(7):e2115342.
Freedman S, Perez V, Fisher M. End of life inpatient spending and hospital advertising. Working paper. https://www.megdalynn.com/wip/2-hospads-eolc
Alpert AE, Lakdawalla DN, Sood N. Prescription drug advertising and drug utilization: the role of Medicare Part D. NBER Working Paper 21714. National Bureau of Economic Research; 2015. https://med.stanford.edu/content/dam/sm/hsr/documents/AlpertHealthEconSeminar_Sep2018.pdf
Umaru OT, Aremu TO. Direct-to-consumer advertising of prescription drugs: what can the Swiss experience tell policy-makers in the United States? Cureus. 2026;18(1):e101400.US
Department of Health and Human Services; US Food and Drug Administration. Ensuring patient safety through reform of direct-to-consumer drug advertising. Fact sheet. Published 2025. https://www.hhs.gov/press-room/hhs-fda-drug-ad-transparency-fact-sheet.html
Campaign for Sustainable Rx Pricing. Analysis: direct-to-consumer advertising report. Published April 2025. https://www.csrxp.org/wp-content/uploads/2025/04/CSRxP-Analysis-Direct-to-Consumer-Advertising-Report.pdf
Dave D, Saffer H. Impact of direct-to-consumer advertising on pharmaceutical prices and demand. South Econ J. 2012;79(1):97-126.